<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110821">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01736865</url>
  </required_header>
  <id_info>
    <org_study_id>DK76092-06</org_study_id>
    <secondary_id>R01DK076092</secondary_id>
    <nct_id>NCT01736865</nct_id>
  </id_info>
  <brief_title>Vitamin D for Established Type 2 Diabetes (DDM2)</brief_title>
  <acronym>DDM2</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts Medical Center</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study in adults with established type 2 diabetes will test whether daily
      vitamin D supplementation affects how the body processes glucose (sugar).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Disposition index</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Disposition index by the insulin secretion sensitivity index-2 (ISSI-2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in glycemia</measure>
    <time_frame>6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in glycemia (categorical variable, composite outcome) defined as [1] a decrease in diabetes medications or [2] a reduction of equal to or more than 0.4 HbA1c units from baseline without increasing medications.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hemoglobin A1c</measure>
    <time_frame>6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in diabetes medications</measure>
    <time_frame>6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Variability of response to vitamin D supplementation in subgroups.</measure>
    <time_frame>6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Variability of response to vitamin D supplementation in subgroups defined by baseline characteristics: (1) race; (3) 25OHD concentration; (3) diabetes treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Effect of vitamin D supplementation on blood 25-hydroxyvitaminD concentration</measure>
    <time_frame>6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Cardiovascular risk factors</measure>
    <time_frame>6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cardiovascular risk factors defined as blood pressure, lipid profile, C-reactive protein and urine albumin excretion</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One placebo pill daily for 1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cholecalciferol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One cholecalciferol pill daily for 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <arm_group_label>cholecalciferol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established type 2 diabetes, defined by one of the following two criteria:

          -  Age ≥ 25 years and ≤ 75 years

          -  BMI: 23 to 40 kg/m2 inclusive

          -  Provision of signed and dated written informed consent prior to any study procedures.

        Major Exclusion Criteria

          -  &quot;Severe&quot; diabetes defined by one of the following criteria:

          -  - (a) Symptoms of hyperglycemia;

          -  - (b) Screening HbA1c ≥ 7.5 [may indicate potential for rapid progression during the
             trial necessitating need to amplify diabetes-specific pharmacotherapy]

          -  History of nephrolithiasis or hypercalcemia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Fuss</last_name>
      <phone>617-636-2834</phone>
      <email>ddm2@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Anastassios Pittas, MD MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati VA Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Rogge</last_name>
      <phone>513-475-6478</phone>
      <email>MaryColleen.Rogge@va.gov</email>
    </contact>
    <investigator>
      <last_name>David D'Alessio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 24, 2013</lastchanged_date>
  <firstreceived_date>November 15, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
